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Abstract Wolfram syndrome is a rare genetic disorder char-
acterized by juvenile-onset diabetes mellitus, diabetes
insipidus, optic nerve atrophy, hearing loss, and neurodegen-
eration. Although there are currently no effective treatments
that can delay or reverse the progression of Wolfram syn-
drome, the use of careful clinical monitoring and supportive
care can help relieve the suffering of patients and improve
their quality of life. The prognosis of this syndrome is current-
ly poor, and many patients die prematurely with severe neu-
rological disabilities, raising the urgency for developing novel
treatments for Wolfram syndrome. In this article, we describe
natural history and etiology, provide recommendations for
diagnosis and clinical management, and introduce new treat-
ments for Wolfram syndrome.
Keywords Wolfram syndrome . Type 1 diabetes . Type 2
diabetes .Blindness .Deafness .Neurodegeneration .βcells .
Genetic disorder . Endoplasmic reticulum stress
Introduction
Wolfram syndrome is an autosomal recessive genetic dis-
order characterized by juvenile-onset diabetes mellitus,
diabetes insipidus, optic nerve atrophy, hearing loss, and
neurodegeneration. It was first reported in 1938 by Wol-
fram and Wagener who found four of eight siblings with
juvenile diabetes mellitus and optic nerve atrophy [1].
Wolfram syndrome is considered a rare disease and esti-
mated to afflict about 1 in 160,000–770,000 [2, 3]. In
1995, Barrett, Bundey, and Macleod described detailed
clinical features of 45 patients with Wolfram syndrome
and determined the best available diagnostic criteria for
the disease [3]. According to the draft International Clas-
sification of Diseases (ICD-11), Wolfram Syndrome is
categorized as a rare specified diabetes mellitus (subcate-
gory 5A16.1, Wolfram Syndrome). The prognosis of this
syndrome is currently poor as most patients die prema-
turely with severe neurological disabilities such as bulbar
dysfunction and organic brain syndrome, with the median
age at death being 30 years (range, 25–49 years), usually
from respiratory failure as a result of brain stem atrophy
[3, 4]. Although there are currently no effective treatments
that can delay, halt, or reverse the progression of Wolfram
syndrome, the use of careful clinical monitoring and sup-
portive care can relieve the debilitating symptoms. In this
article, we provide recommendations for diagnosis and
clinical management and introduce potential new treat-
ments for Wolfram syndrome.
Common Clinical Presentations and Natural History
The common manifestations of Wolfram syndrome in-
clude diabetes mellitus, optic nerve atrophy, central di-
abetes insipidus, sensorineural deafness, urinary tract
problems, and progressive neurologic difficulties. Dia-
betes mellitus is typically the first manifestation, usual-
ly diagnosed around age 6 [3]. Optic nerve atrophy,
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marked by loss of color vision and peripheral vision,
follows around age 11 [3]. Central diabetes insipidus
is another common manifestation, affecting approxi-
mately 70 % of Wolfram patients [3]. Around 65 % of
patients develop sensorineural deafness that can range
in severity from deafness beginning at birth to mild
hearing loss beginning in adolescence that worsens
over time [3, 4]. Urinary tract problems are another
major clinical challenge for Wolfram syndrome patients
affecting 60 to 90 % of this population. These problems
include obstruction of the ducts between the kidneys
and bladder, high-capacity atonal bladder, disrupted
urination, bladder sphincter dyssynergia, and difficulty
controlling urine flow [3]. More than 60 % of patients
with Wolfram syndrome develop neurological manifes-
tations, most commonly presenting as problems with
balance and coordination (ataxia) beginning in early
adulthood. Brain stem atrophy is also a prominent fea-
ture that often results in death secondary to central ap-
nea [3, 5, 6]. Other symptoms reported in patients with
Wolfram syndrome are listed in Fig. 1 and the Wash-
ington University Wolfram Syndrome Clinical Study
Website (http://wolframsyndrome.dom.wustl.edu/).
Clinical manifestations related to mood disorder and
autonomic dysfunction are commonly seen [7, 8].
These are probably related to dysfunction and/or death
of neurons due to the defects in the secretion of neuro-
transmitters and neurotrophic factors. There is currently
no effective therapy that can delay the progression of
Wolfram syndrome, thus raising the urgency for devel-
oping novel treatments.
Diagnosis of Wolfram Syndrome
Clinical Diagnosis
It is important for physicians to provide an accurate and
prompt diagnosis of Wolfram syndrome, which allows us to
provide patients with support and education and initiate ap-
propriate interventions. Suspicion of the diagnosis ofWolfram
syndrome is usually based on history and clinical manifesta-
tions. Most commonly, the observation of optic nerve atrophy
after the diagnosis of diabetes mellitus under the age of 16
triggers the suspicion. Increasing evidence indicates that Wol-
fram syndrome is a spectrum disorder. Diabetes insipidus,
sensorineural deafness, neurological signs including ataxia,
autonomic neuropathy, and epilepsy, and neurogenic bladder
in combination with diabetes mellitus or optic nerve atrophy
could be a sign of Wolfram syndrome. The differential diag-
noses include mitochondrial disorders, mutant WFS1 gene-
induced deafness, autosomal dominant optic nerve atrophy,
Friedreich ataxia, Bardet–Biedl syndrome, and Alstr m
syndrome.
Confirmation of the Diagnosis
Although the medical and family histories and the findings of
the physical examination are vital for the diagnosis of Wol-
fram syndrome, genetic testing has been proven to be useful to
confirm the diagnosis. The development of genetic tests for
this syndrome has identifiedWFS1 as the main locus mutated
in the majority of this patient population [9]. Sanger
sequencing-based genetic testing of the WFS1 gene usually
confirms the diagnosis. Majority of patients have recessive
mutations in the WFS1 gene, but several dominant mutations
have been discovered in our patient population, including
H313Y [10]. Dominant mutations in the WFS1 gene are a
common cause of low-frequency sensorineural hearing loss
[11, 12]. We have recently discovered patients with autosomal
dominant diabetes arising from a WFS1 mutation [13]. Thus,
the interpretation of genetic testing results requires specialized
knowledge. A small number of patients carry recessive muta-
tions in the CISD2 (WFS2) gene [14]. We perform Sanger
sequencing-based genetic testing of theWFS2 gene in patients
who do not carry mutations in the WFS1 gene. We are cur-
rently developing exome sequencing- and genome
sequencing-based diagnostic methods for Wolfram syndrome
and Wolfram-related disorders (Fig. 2).Fig. 1 Common clinical manifestations in Wolfram syndrome
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Clinical Management
Urological Manifestations
Structural and functional urinary tract abnormalities are
commonly seen in patients with Wolfram syndrome and
significantly affect quality of life. Yearly assessment of
renal function, measurement of postvoid residual urine
volume by ultrasound, a renal ultrasound, and urodynamic
testing are recommended. A large atonic bladder, a low-
capaci ty, high-pressure bladder with sphincteric
dyssynergia, and hydroureteronephrosis are common
manifestations [3, 4, 15]. We suspect that both bladder
dysfunction and upper urinary tract dilatation are primary
manifestations although these symptoms may be partially
affected by diabetes mellitus and diabetes insipidus. The
treatment options for bladder dysfunction include anticho-
linergic drugs and clean intermittent catheterization. Elec-
trical stimulation and physiotherapy have been effective
in some patients.
Recurrent urinary tract infection (UTI) is one of the most
common clinical challenges in patients with Wolfram syn-
drome. The bladder dysfunction caused by the central and
peripheral neurologic dysfunction is thought to be the under-
lying cause of UTI. Urine culture is recommended for Wol-
fram patients with fever or other symptoms, such as headache.
Inflammatory conditions associated with UTI may cause
headache and other symptoms.
Ophthalmologic Manifestations
Optic nerve atrophy with resultant loss of visual acuity is a
cardinal feature ofWolfram syndrome and the biggest concern
for patients. Yearly eye examination, including visual acuity,
color vision testing, fundoscopy, visual field, and optical co-
herence tomography (OCT) scan, is strongly recommended.
Visual evoked potentials are useful to monitor the efficacy of
potential treatments. Retinal thinning has been shown to be a
reliable marker for the disease progression [16, 17]. Magnifi-
cation of images on smartphone and tablets, or by magnifying
glasses, and voice systems are helpful. Some patients develop
cataracts in childhood, and surgery is needed. There are cur-
rently no proven effective medical therapies for optic nerve
atrophy in Wolfram syndrome. It has been suggested that the
use of idebenone or docosahexaenoic acid may be beneficial
for delaying the progression of optic nerve atrophy, but the
efficacy has not be confirmed by large-scale interventional
studies [18, 19••].
Hearing Manifestations
Sensorineural hearing loss is one of the common symptoms of
Wolfram syndrome and observed in around 70 % of patients
[20, 21]. The hearing loss affects the high frequencies first and
progresses relatively slowly [3, 4, 22]. Routine audiometry is
recommended every year or every 2 years. Auditory brainstem
response (ABR) audiometry should be performed at diagnosis
to confirm the pathophysiology and examine the efficacy of
any treatments. Management includes hearing aids and co-
chlear implant. Hearing manifestations in Wolfram syndrome
should be carefully examined because dominant mutations in
the WFS1 gene are a common cause of low-frequency senso-
rineural hearing loss, which is different from Wolfram syn-
drome [11, 12, 23]. These patients develop low-frequency
sensorineural hearing loss but do not develop other symptoms
seen in patients with Wolfram syndrome, such as diabetes
mellitus and ataxia.
Neurological Manifestations
Multiple neurological conditions are seen in patients with
Wolfram syndrome, including ataxia, central apnea related to
brain stem atrophy, autonomic neuropathy, peripheral neurop-
athy, inability or decreased ability to detect odors, inability or
decreased ability to taste, hypersomnolence, headache, and
seizures. The following conditions are common major
Fig. 2 Development of diagnostics and therapeutics for Wolfram
syndrome
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problems in our patients and strongly associated with neuro-
degeneration with Wolfram syndrome.
Ataxia and Dysphagia
Wolfram syndrome is characterized by progressive neurode-
generation. The most common problem is ataxia. Cerebellar
ataxia should be assessed yearly or twice a year by neurolo-
gists. Dysarthria and swallowing disorders (dysphagia) are
commonly seen. Swallowing treatment by a speech-
language pathologist is beneficial for patients to prevent aspi-
ration pneumonia. Surgical procedures, including esophageal
dilation and esophagomyotomy, have been shown to be effec-
tive in some patients. Oral hygiene and dental care are impor-
tant because dysphagia may lead to the impaired clearance of
organisms and pathogenic colonization.
Brain Stem Atrophy
Brain stem atrophy is a prominent feature that often results in
death secondary to central apnea [3]. Polysomnography, as
well as overnight oximetry test, can be used as screening stud-
ies. Central apnea should be managed by a pulmonologist.
Some patients may require tracheostomy.
Autonomic Neuropathy
Autonomic neuropathy is commonly seen in patients with
Wolfram syndrome. Signs and symptoms include orthostatic
hypotension, anhidrosis, hypohidrosis, hyperhidrosis, consti-
pation, gastroparesis, hypothermia, and hyperpyrexia. A thor-
ough history and review of systems may reveal most of these
complaints. Gastrointestinal conditions can be managed by
changes in diet, small frequent meals, increased fiber diet,
and increased water intake.
Headache
Headachemay be related to autonomic dysfunction or neurop-
athy. Some patients experience sharp and stabbing unilateral
pain similar to trigeminal neuralgia. A consultation with a
neurologist is recommended. Carbamazepine or amitriptyline
has been shown to be effective in some patients.
Psychiatric Manifestations
Anxiety and depression are commonly seen [7, 8, 24]. Psy-
chosis is seen in some patients but not very common. A con-
sultation with a psychiatrist is recommended. Anxiety and
depression are treatable in standard way. Cognitive function
is usually normal in patients with Wolfram syndrome, espe-
cially in younger patients [25].
Endocrine Manifestations
Diabetes mellitus and diabetes insipidus are the most common
clinical manifestations of Wolfram syndrome. These are treat-
able conditions, and follow-up and management should be
done in standard way. The following conditions are associated
with endocrine system dysfunction.
Hyponatremia
Most patients with Wolfram syndrome have diabetes mellitus
and bladder dysfunction in combination with diabetes
insipidus. The dose escalation of desmopressin for the treat-
ment of diabetes insipidus should be carefully done because
demopressin may cause hyponatremia. Hyponatremia is a
common clinical problem in patients with Wolfram syndrome
that requires careful management.
Hypogonadism
Hypogonadism is seen in some patients. Impaired fertility and
erectile dysfunction in male patients and infertility, amenor-
rhea, and oligomenorrhea in female patients have been report-
ed. These conditions could be treatable and managed in stan-
dard way.
Novel Treatments
Etiology and Drug Targets
Wolfram syndrome was initially categorized as a mitochon-
drial disease due to its symptoms and several reports of mito-
chondrial mutations. However, it has now been established
that Wolfram syndrome is a prototype of endoplasmic reticu-
lum (ER) disease [26–28]. The ER is a membrane network
within our cells that is involved in protein synthesis, calcium
storage, redox regulation, steroid synthesis, cell signaling, and
cell death. Previous studies have shown that pancreaticβ cells
and neurons are particularly sensitive to ER dysfunction, like-
ly due to their high rates of protein synthesis [29]. In Wolfram
syndrome, pancreaticβ cells and neuronal cells are selectively
destroyed as a consequence of mutations in the WFS1 gene.
This gene encodes a transmembrane protein localized to the
ER, suggesting that ER dysfunction is a major pathogenic
component of Wolfram syndrome. In Wolfram syndrome,
WFS1 mutations lead to elevated ER stress levels, pancreatic
β cell dysfunction, and the initiation of ER stress-associated
cell death [28, 30].We have recently reported that depletion of
ER calcium and subsequent activation of calpain play a role in
β cell death in neurodegeneration in Wolfram syndrome
[19••]. A small portion of patients have mutations in the
WFS2 (CISD2) gene [14, 31, 32]. WFS2 also encodes a
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transmembrane protein localized to the ER [14]. In patients
with WFS2 mutations, diabetes mellitus and hearing impair-
ment are reported. Their clinical phenotype differs from pa-
tients carrying WFS1 mutations for the absence of diabetes
insipidus and for the presence of upper intestinal ulcers and
defective platelet aggregation [32], suggesting that there are
different and overlapping functions of WFS1 and WFS2.
Targeting Endoplasmic Reticulum Dysfunction
with Currently Available Drugs—Drug Repurposing
One strategy for expediting the development of new ther-
apeut ic opt ions for Wolfram syndrome is drug
repurposing (Fig. 2) [33]. Drug repurposing is the use of
currently approved drugs by regulatory agencies, such as
the United States Food and Drug Administration (FDA)
and the European Commission and the European Medi-
cines Agency (EMA), to find therapies for other diseases.
This is an attractive therapeutic option because the devel-
opment of novel treatment compounds takes a lot of time
and money, which can be avoided by the use of readily
available FDA-approved drugs. In the treatment of Wol-
fram syndrome, drugs can be targeted to several areas of
ER dysfunction including modulators of ER stress, ER
calcium homeostasis, and cellular proteostasis [34–36].
Chemical chaperones are small compounds which can
stabilize protein conformation during folding and improve
trafficking of mutant proteins through the ER [37]. Cur-
rently, there are two FDA-approved chemical chaperones,
4-phenylbutyric acid (PBA) and tauroursodeoxycholic ac-
id (TUDCA). In WFS1-deficient β cells, there is an in-
creased level of ER stress and decreased insulin content,
both of which can be normalized by treatment with chap-
erones [38•]. This suggests that PBA and TUDCA may
improve β cell functions and prevent ER stress-mediated
β cell death and neurodegeneration in patients with Wol-
fram syndrome.
Proper function of the ER requires a steep calcium gradi-
ent; without this gradient, cells undergo ER stress and cell
death. Thus, targeting drugs known to maintain ER calcium
levels during ER stress presents a novel therapeutic target for
Wolfram syndrome. In β cells, ER stress has been shown to
elicit ER calcium depletion resulting in β cell death, which
can be prevented with pharmacologic restoration of ER calci-
um levels [39]. Several currently FDA-approved compounds
have been shown to preserve ER calcium levels in response to
ER stress. We have recently discovered that dantrolene which
targets ryanodine receptor localized to the ER membrane pre-
vents β cell death and neurodegeneration in animal models
and cell models withWolfram syndrome [19••]. Interventional
studies using dantrolene and other ER calcium stabilizers
should be considered.
Development of Drugs Targeting the Endoplasmic
Reticulum
Because currently available drugs are not specifically de-
signed to target ER stress or ER dysfunction, we should
create novel small molecules to control ER homeostasis in
Wolfram syndrome in addition to using FDA-approved
drugs (Fig. 2). There are three major pillars that sustain
ER homeostasis: calcium homeostasis, redox regulation,
and protein folding. Accumulating evidence suggests that
WFS1 protein plays a role in maintaining ER calcium
homeostasis, raising the possibility that small molecules
that can regulate ER calcium levels may prevent cell
death in Wolfram syndrome. One of the major genes re-
quired for ER calcium homeostasis in β cells is sarco/
endoplasmic reticulum Ca2+-ATPase (SERCA) [40]. It
has been reported that WFS1 binds to SERCA and mod-
ulates its function [41]. Thus, a small molecule that can
Fig. 3 Power of Wolfram syndrome. It has been established that
endoplasmic reticulum (ER) dysfunction and ER stress are critical
pathogenic components of Wolfram syndrome. It would be possible to
identify biomarkers and treatments targeting ER in mechanistically
homogenous Wolfram syndrome patients, which may lead to a
breakthrough for treatments of common diseases, such as type 1
diabetes, type 2 diabetes, and neurodegeneration, in which ER
dysfunction is involved
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activate SERCA and maintain high ER calcium levels
under pathological conditions could prevent death of neu-
rons and β cells in Wolfram syndrome. Another possibil-
ity is to target calcium channels in the ER, such as
ryanodine receptors and inositol trisphosphate receptors.
We have recently reported that dantrolene which targets
ryanodine receptors can prevent the death of neurons and
β cells in Wolfram syndrome using mouse models and
induced pluripotent stem cell (iPSC) models of the dis-
ease [19••]. We are currently developing novel therapeu-
tics using small molecules targeting these mediators of ER
calcium homeostasis in collaboration with the drug devel-
opment team at the National Center for Advancing Trans-
lational Sciences, National Institutes of Health.
Regenerative Therapy and Gene Therapy for Wolfram
syndrome
Our first goal is to stop the progression of Wolfram syn-
drome using FDA-approved drugs or novel small mole-
cules targeting the ER. In parallel, we need to figure out a
way to replace damaged tissues, such as pancreatic β cells
and retinal cells, in patients with Wolfram syndrome. Rap-
id progress in the field of regenerative medicine may
make this possible in the near future [42] (Fig. 2). Our
strategy is to create induced pluripotent stem (iPS) cells
using patients’ skin cells, correct WFS1 gene mutations
with genome editing technology, and differentiate these
iPS cells into insulin-producing β cells, retinal cells, and
neurons for transplantation [43•]. We are currently using
the Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR) technology. We are also testing if mes-
encephalic astrocyte-derived neurotrophic factor (MANF),
a regeneration factor purified from astrocytes, can prevent
cell death and activate the proliferation of remaining β
cells, neurons, and retinal ganglion cells by leveraging
our natural ability to regenerate damaged tissues [44, 45].
Conclusion
Multidisciplinary Care and Partnership with Patient
Organizations
Wolfram syndrome affects different organs and systems in
the body. Thus, multidisciplinary care by physicians and
healthcare professionals from a range of disciplines is re-
quired. Based on our experience, a strong patient-doctor
partnership can facilitate the communication between
physicians in different specialties. Patient organizations
have played an important role to encourage physicians
from different specialties, clinics, hospitals, and even
countries to work together. The strong partnership
between physicians, researchers, and patient organizations
is also important to conduct successful clinical trials.
Power of Wolfram Syndrome
Increasing evidence indicates that ER stress and ER dys-
function play important roles in the pathogenesis of com-
mon diseases, such as type 1 and type 2 diabetes, as well
as multiple neurodegenerative diseases [46]. Its monogen-
ic etiology makes Wolfram syndrome more amenable to
revealing the mechanisms of ER stress-mediated cell
death than other common conditions in which multiple
factors typically interact to produce the disease manifes-
tations. Thus, Wolfram syndrome represents an ideal mod-
el to shed new light on the underlying causes of β cell
death in diabetes, neurodegeneration, and retinal cell
death mediated by ER dysfunction.
We believe in the strong power of Wolfram syndrome
to understand the pathogenesis and develop novel thera-
peutic modalities for more prevalent diseases. Our study
on Wolfram may lead to a breakthrough for treatments of
not only Wolfram syndrome but also common diseases,
such as type 1 diabetes, type 2 diabetes, and neurodegen-
eration, in which ER dysfunction is involved (Fig. 3).
Acknowledgments The author thanks all of the participants in theWol-
fram syndrome International Registry and Research Clinic for their time
and efforts and the Washington University Wolfram Study Group Mem-
bers and the study staff for their support (http://wolframsyndrome.dom.
wustl.edu/). The author also thanks patient organizations, including
Wolfram UK, Association du Syndrome de Wolfram in France,
Associacion Sindrome de Wolfram in Spain, Wolfram syndrome patient
organization in Italy, Worldwide Society ofWolfram Syndrome Families,
the Ellie White Foundation for Rare Genetic Disorders, and the Snow
Foundation for their continued encouragement and support, the members
of EURO-WABB for their advice and support, the members of Global
Rare Diseases Patient Registry and Data Repository Program of NIH/
NCATS, and the drug development team at NIH/NCATS. This work
was supported by grants from NIH (DK067493, DK020579, and UL1
TR000448), JDRF (17-2013-512), ADA (1-12-CT-61), the Ellie White
Foundation for Rare Genetic Disorders, the Team Ian, the Team
Alejandro, and the Snow Foundation to F. Urano.
Compliance with Ethical Standards
Conflict of Interest Fumihiko Urano has received grants from
Amarantus BioScience, Ono Pharmaceutical, and Hope Therapeutics;
received speaker honorarium fromTakeda Pharmaceuticals; and is a stock
holder for CytRx. He has a pending patent for Treatment for Wolfram
Syndrome and Other Endoplasmic Reticulum Stress Disorders, and a
license patent for Soluble MANF in Pancreatic Beta-Cell Disorders.
Human and Animal Rights and Informed Consent Wolfram syn-
drome patients were recruited through the Washington University
Wolfram Syndrome International Registry website (http://
wolframsyndrome.dom.wustl.edu/). The human study protocol was
approved by the Washington University Human Research Protection
Office, and all subjects provided informed consent if adults and
assent with consent by parents if minor children (IRB ID
6 Page 6 of 8 Curr Diab Rep (2016) 16: 6
201107067). All animal experiments were performed according to
procedures approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine
(A-3381-01).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Wolfram DJ, Wagener HP. Diabetes mellitus and simple optic atro-
phy among siblings: report of four cases. Mayo Clin Proc. 1938;1:
715–8.
2. Kinsley BT, Swift M, Dumont RH, et al. Morbidity andmortality in
the Wolfram syndrome. Diabetes Care. 1995;18(12):1566–70.
3. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and dia-
betes: UK nationwide study of Wolfram (DIDMOAD) syndrome.
Lancet. 1995;346(8988):1458–63.
4. Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med
Genet. 1997;34(10):838–41.
5. Hershey T, Lugar HM, Shimony JS, et al. Early brain vulnerability
in wolfram syndrome. PLoS One. 2012;7(7):e40604. doi:10.1371/
journal.pone.0040604.
6. Zmyslowska A, Malkowski B, Fendler W, et al. Central nervous
system PET-CT imaging reveals regional impairments in pediatric
patients with Wolfram syndrome. PLoS One. 2014;9(12):e115605.
doi:10.1371/journal.pone.0115605.
7. Swift RG, Sadler DB, Swift M. Psychiatric findings in Wolfram
syndrome homozygotes. Lancet. 1990;336(8716):667–9.
8. Swift RG, Perkins DO, Chase CL, et al. Psychiatric disorders in 36
families with Wolfram syndrome. Am J Psychiatry. 1991;148(6):
775–9.
9. Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a trans-
membrane protein is mutated in patients with diabetes mellitus and
optic atrophy (Wolfram syndrome). Nat Genet. 1998;20(2):143–8.
10. Hansen L, Eiberg H, Barrett T, et al. Mutation analysis of theWFS1
gene in seven Danish Wolfram syndrome families; four new muta-
tions identified. Eur J Hum Genet. 2005;13(12):1275–84. doi:10.
1038/sj.ejhg.5201491.
11. Bespalova IN, Van Camp G, Bom SJ, et al. Mutations in the
Wolfram syndrome 1 gene (WFS1) are a common cause of low
frequency sensorineural hearing loss. Hum Mol Genet.
2001;10(22):2501–8.
12. Lesperance MM, Hall 3rd JW, San Agustin TB, et al. Mutations in
the Wolfram syndrome type 1 gene (WFS1) define a clinical entity
of dominant low-frequency sensorineural hearing loss. Arch
Otolaryngol Head Neck Surg. 2003;129(4):411–20. doi:10.1001/
archotol.129.4.411.
13. Bonnycastle LL, Chines PS, Hara T, et al. Autosomal dominant
diabetes arising from a wolfram syndrome 1 mutation. Diabetes.
2013;62(11):3943–50. doi:10.2337/db13-0571.
14. Amr S, Heisey C, Zhang M, et al. A homozygous mutation in a
novel zinc-finger protein, ERIS, is responsible for Wolfram syn-
drome 2. Am J Hum Genet. 2007;81(4):673–83. doi:10.1086/
520961.
15. Tekgul S, Oge O, Simsek E, et al. Urological manifestations of the
Wolfram syndrome: observations in 14 patients. J Urol.
1999;161(2):616–7.
16. Hoekel J, Chisholm SA, Al-Lozi A, et al. Ophthalmologic corre-
lates of disease severity in children and adolescents with Wolfram
syndrome. J AAPOS. 2014;18(5):461–5. doi:10.1016/j.jaapos.
2014.07.162. e1.
17. Zmyslowska A, Fendler W, Niwald A, et al. Retinal thinning as a
marker of disease progression in patients with Wolfram syndrome.
Diabetes Care. 2015;38(3):e36–7. doi:10.2337/dc14-1898.
18. Bababeygy SR, Wang MY, Khaderi KR, et al. Visual improvement
with the use of idebenone in the treatment of Wolfram syndrome. J
Neuroophthalmol. 2012;32(4):386–9. doi:10.1097/WNO.
0b013e318273c102.
19.•• Lu S, Kanekura K, Hara T, et al. A calcium-dependent protease as a
potential therapeutic target for Wolfram syndrome. Proc Natl Acad
Sci U S A. 2014;111(49):E5292–301. doi:10.1073/pnas.
1421055111. This article describes that the leakage of
endoplasmic reticulum calcium to the cytosol and subsequent
activation of calpain 2 are the key molecular events leading to
cell death in Wolfram syndrome. The article further reports
that dantrolene, a FDA-approved drug targeting ryanodine re-
ceptor localized to the ER, is a potential drug for Wolfram
syndrome.
20. Higashi K. Otologic findings of DIDMOAD syndrome. Am J Otol.
1991;12(1):57–60.
21. Kumar S. Wolfram syndrome: important implications for pediatri-
cians and pediatric endocrinologists. Pediatr Diabetes. 2010;11(1):
28–37. doi:10.1111/j.1399-5448.2009.00518.x.
22. Karzon RK, Hullar TE. Audiologic and vestibular findings in
Wolfram syndrome. Ear Hear. 2013;34(6):809–12. doi:10.1097/
AUD.0b013e3182944db7.
23. Cryns K, Sivakumaran TA, Van den Ouweland JM, et al.
Mutational spectrum of the WFS1 gene in Wolfram syndrome,
nonsyndromic hearing impairment, diabetes mellitus, and psychi-
atric disease. Hum Mutat. 2003;22(4):275–87.
24. Swift M, Swift RG. Wolframin mutations and hospitalization for
psychiatric illness. Mol Psychiatry. 2005;10(8):799–803.
25. Bischoff AN, Reiersen AM, Buttlaire A, et al. Selective cognitive
and psychiatric manifestations in Wolfram Syndrome. Orphanet J
Rare Dis. 2015;10:66. doi:10.1186/s13023-015-0282-1.
26. Ishihara H, Takeda S, Tamura A, et al. Disruption of theWFS1 gene
in mice causes progressive beta-cell loss and impaired stimulus-
secretion coupling in insulin secretion. Hum Mol Genet.
2004;13(11):1159–70.
27. Riggs AC, Bernal-Mizrachi E, Ohsugi M, et al. Mice conditionally
lacking the Wolfram gene in pancreatic islet beta cells exhibit dia-
betes as a result of enhanced endoplasmic reticulum stress and
apoptosis. Diabetologia. 2005;48(11):2313–21.
28. Fonseca SG, Fukuma M, Lipson KL, et al. WFS1 is a novel com-
ponent of the unfolded protein response and maintains homeostasis
of the endoplasmic reticulum in pancreatic {beta}-cells. J Biol
Chem. 2005;280(47):39609–15.
29. Fonseca SG, Gromada J, Urano F. Endoplasmic reticulum stress
and pancreatic beta-cell death. Trends Endocrinol Metab.
2011;22(7):266–74. doi:10.1016/j.tem.2011.02.008.
30. Fonseca SG, Ishigaki S, Oslowski CM, et al. Wolfram syndrome 1
gene negatively regulates ER stress signaling in rodent and human
cells. J Clin Invest. 2010;120(3):744–55. doi:10.1172/JCI39678.
31. Ajlouni K, Jarrah N, El-Khateeb M, et al. Wolfram syndrome: iden-
tification of a phenotypic and genotypic variant from Jordan. Am J
Med Genet. 2002;115(1):61–5. doi:10.1002/ajmg.10345.
Curr Diab Rep (2016) 16: 6 Page 7 of 8 6
32. Mozzillo E, Delvecchio M, Carella M, et al. A novel CISD2 intra-
genic deletion, optic neuropathy and platelet aggregation defect in
Wolfram syndrome type 2. BMC Med Genet. 2014;15:88. doi:10.
1186/1471-2350-15-88.
33. Urano F. Diabetes: targeting endoplasmic reticulum to combat ju-
venile diabetes. Nat Rev Endocrinol. 2014;10(3):129–30. doi:10.
1038/nrendo.2013.261.
34. Ramadan JW, Steiner SR, O'Neill CM, et al. The central role of
calcium in the effects of cytokines on beta-cell function: implica-
tions for type 1 and type 2 diabetes. Cell Calcium. 2011;50(6):481–
90. doi:10.1016/j.ceca.2011.08.005.
35. Calamini B, Morimoto RI. Protein homeostasis as a therapeutic
target for diseases of protein conformation. Curr Top Med Chem.
2012;12(22):2623–40.
36. Engin F, Yermalovich A, Nguyen T, et al. Restoration of the un-
folded protein response in pancreatic beta cells protects mice
against type 1 diabetes. Sci Transl Med. 2013;5(211):211ra156.
doi:10.1126/scitranslmed.3006534.
37. Welch WJ, Brown CR. Influence of molecular and chemical chap-
erones on protein folding. Cell Stress Chaperones. 1996;1(2):109–
15.
38.• Shang L, Hua H, Foo K, et al. β-cell dysfunction due to increased
ER stress in a stem cell model of wolfram syndrome. Diabetes.
2014;63(3):923–33. doi:10.2337/db13-0717. This article reports
the establishment of iPS models of Wolfram syndrome that can
be utilized to determine drugs for the treatment of Wolfram
syndrome.
39. Hara T, Mahadevan J, Kanekura K, et al. Calcium efflux from the
endoplasmic reticulum leads to beta-cell death. Endocrinology.
2014;155(3):758–68. doi:10.1210/en.2013-1519.
40. Cardozo AK, Ortis F, Storling J, et al. Cytokines downregulate the
sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete
endoplasmic reticulum Ca2+, leading to induction of endoplasmic
reticulum stress in pancreatic beta-cells. Diabetes. 2005;54(2):452–
61.
41. Zatyka M, Da Silva Xavier G, Bel lomo EA, et a l .
Sarco(endo)plasmic reticulum ATPase is a molecular partner of
Wolfram syndrome 1 protein, which negatively regulates its ex-
pression. Hum Mol Genet. 2014. doi:10.1093/hmg/ddu499.
42. Tabar V, Studer L. Pluripotent stem cells in regenerative medicine:
challenges and recent progress. Nat Rev Genet. 2014;15(2):82–92.
doi:10.1038/nrg3563.
43.• Urano F.Wolfram syndrome iPS cells: the first human cell model of
endoplasmic reticulum disease. Diabetes. 2014;63(3):844–6. doi:
10.2337/db13-1809. This article articulates a new strategy for
the development of novel treatments for Wolfram syndrome.
44. Petrova P, Raibekas A, Pevsner J, et al. MANF: a new mesence-
phalic, astrocyte-derived neurotrophic factor with selectivity for
dopaminergic neurons. J Mol Neurosci. 2003;20(2):173–88.
45. Lindahl M, Danilova T, Palm E, et al. MANF is indispensable for
the proliferation and survival of pancreatic beta cells. Cell Rep.
2014;7(2):366–75. doi:10.1016/j.celrep.2014.03.023.
46. Wang S, Kaufman RJ. The impact of the unfolded protein response
on human disease. J Cell Biol. 2012;197(7):857–67. doi:10.1083/
jcb.201110131.
6 Page 8 of 8 Curr Diab Rep (2016) 16: 6
